---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048285"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T12:15:40.319401+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reverses insulin resistance to near pre-diabetes in zebrafish T2D study

## Summary
- Telomir-1 restored glucose homeostasis, reducing HOMA-IR values and improving oral glucose tolerance in zebrafish model.
- Dose-dependent normalization of blood glucose levels observed; insulin resistance reversed to near pre-diabetes levels.
- Novel mechanism targets iron metabolism to address oxidative stress and beta-cell damage, root causes of Type 2 diabetes.
- Treated models showed increased survival rates, reinforcing therapeutic potential of Telomir-1.

## SEC filing metadata
- accession: 0001493152-24-048285
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/0001493152-24-048285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048285
- JSON: https://secwatch.observer/filing/0001493152-24-048285.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.